enGene Holdings CMO Resignation Announced

enGene Holdings ( (ENGN) ) has provided an announcement.

On June 3, 2025, Dr. Raj S. Pruthi announced his resignation as Chief Medical Officer of enGene Holdings, effective June 16, 2025. The company plans to redistribute his responsibilities among other urology and clinical experts to ensure a smooth transition. This change is part of enGene’s ongoing efforts to maintain its strategic focus on advancing its genetic medicine programs, particularly in the field of bladder cancer treatment.

The most recent analyst rating on (ENGN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.

Spark’s Take on ENGN Stock

According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.

enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.

To see Spark’s full report on ENGN stock, click here.

More about enGene Holdings

enGene Holdings Inc. is a clinical-stage biotechnology company that focuses on genetic medicines, particularly targeting mucosal tissues and other organs. Their lead program, detalimogene voraplasmid, is being developed for Non-Muscle Invasive Bladder Cancer and is currently in a Phase 2 study.

Average Trading Volume: 58,759

Technical Sentiment Signal: Sell

Current Market Cap: $203.3M

Find detailed analytics on ENGN stock on TipRanks’ Stock Analysis page.